Yeah that sad little rat is lurking in the shadows ...
Yeah that sad little rat is lurking in the shadows ... LMAO
Here is a good post that probably will be removed by the Imafia, but I saved it before they could... So keep this, and similar posts in your Archive folders and post them to newbies coming to the Islut board via PM's.
gamecock23
Share
Thursday, May 17, 2012 2:11:40 AM
Re: MVP_STOCKS post# 99252
Post # of 99316
Hello all,
I have been watching this site for a few months now. Tonight I decided to join so I could post. I have done extensive DD, and I have found absolutely no verification concerning your post. Matt Dwyer is in no way involved in any of these lawsuits. As a matter of fact, the only time it appears is when you add it to your post. I have also heard the .0001 or nobid claims for months now, and guess what, still no relevance. I have a hard time understanding your logic. Here are the verifiable facts that you can find in black and white.
1. The SEC approved Baron's TA
2. FINRA approved the name change ( this comes with a very in depth investigation along with your 50 dollar fee)
3. Audits are happening, your earlier post about having them done in two or three weeks is ridiculous. It is apparent that you have little to no knowledge of what you post!
4. Liabilities have been reduced tremendously and will be decreased by 270,000 by Q2. Which is outstanding!
5. The AS has been reduced by over 97 BILLION! And the SS has not changed since 2011. So there is no dilution and he is not dumping.
6. While you post nonsense the company is getting ready to have a private placement to raise more money to purchase a BD. Before you think about posting nonsense, the shares are restricted and non-dilutive.
7. THERE IS ABSOLUTELY NO INVESTIGATION, NO CASE NUMBER, AND NO CHILL.
Your DD is not verifiable, as a matter of fact it is juvenile rubbish.
Cock
Baron Capital Enterprise, INC. (BCAP) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
SVRN Aims for New Heights with a Savvy Hire If there’s one thing veteran market-watchers like myself know, it’s that leadership shifts can tell you more about a company’s guts than any press release. SVRN (NASDAQ: SVRN), a name with one foot firmly in the world of digital assets, just snagged Patrick O’Kain for their COO spot. They're not playing around, folks,...
Continue Reading
Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...
Continue Reading
Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....
Continue Reading
Securities Law Tangles: Coastal Financial Hits a Snag There's no dodging it—Coastal Financial Corporation's dogged by a class action lawsuit, and investors need to sit up and take notice. This kind of legal fracas can hit the stock price like a brick through a window, especially when alleged securities law violations crop up. DJS Law Group's got the reins on this one,...
Continue Reading
Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...
Continue Reading
Brooklyn's Gem: MAURE Turns Three Over in Brooklyn, there's a brand bubbling with style called MAURE. Now, we're talking three years strong, surviving the wild bout of the retail scene with a firm two feet planted in home and gifting. The Vision Turned Reality When Maureen Cavalieri, a hospitality veteran since 2009, first tossed this spark into the wind in 2023, it...
Continue Reading
Pushing the Horizons in Hematological Research From the bustling streets of Shanghai to the global stage of the ASH 2026, Dizal has made its mark again. This year's presentations could very well shake up the hematological landscape, showcasing new possibilities for treatment strategies. Golidocitinib: A Game-Changer? Now here's a ticket we've been watching with some high...
Continue Reading
Pardon my skepticism, but when a roofing company names itself Life of Abundance, you know they're aiming to hit it big or at least make you think they're onto something special. LOA Roofing and Construction, holding its ground as a major player in the Central Texas market, set the stage for more ambitious growth. And they found themselves a dance partner in Southstone...
Continue Reading
SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...
Continue Reading
Unpacking Lilly's Latest Rheumatology Innovations Lilly's taking the stage at ACR Convergence 2026 with a potent arsenal of data that’s got folks buzzing. The company’s put the pedal to the metal on understanding the intertwining chords of obesity and rheumatologic conditions, and boy, are they not messing around. Retatrutide: A Triple Threat in the Making Headlining...
Continue Reading
Top 5 Most Recently Viewed Articles
SKYX Technologies' Corporate Developments SKYX Technologies, also known as SKYX (NASDAQ: SKYX), is taking significant strides in the smart technology sector. This dynamic company focuses on transforming homes and buildings into smarter, safer, and more advanced spaces. With a remarkable portfolio of over 97 issued and pending patents, SKYX aims to set a new standard in...
Continue Reading
Crinetics Pharmaceuticals Enhances Employee Incentives In a recent announcement, Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), based in San Diego, revealed a significant step in enhancing employee incentives and strengthening its workforce. On October 10, 2025, the company’s Compensation Committee authorized the granting of stock options and restricted stock units...
Continue Reading
Manulife Investment Management Recognized for Excellence In a significant acknowledgment of its leadership in sustainable finance, Manulife Investment Management (Manulife IM) has made it to the prestigious list of IPE Real Assets' Top 50 Natural Capital Managers. This recognition comes as the firm is gearing up for robust fundraising activities, with an exciting fund...
Continue Reading
Vaxart’s Business Progress and Financial Results Overview Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, recently provided a significant update on its business and reported its financial outcomes for the third quarter of 2025. This latest communication showcases exciting developments in their oral recombinant vaccine platform, which is designed to...
Continue Reading
Madrigal Pharmaceuticals Achieves Enrollment Milestone in NASH Study Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company dedicated to developing innovative therapies for liver diseases, has announced a significant milestone in their MAESTRO-NASH OUTCOMES clinical trial. This study evaluates the efficacy of resmetirom in patients diagnosed with...
Continue Reading